| Abigail Bargiel Burns, RN | |
|
390 River St, Springfield, VT 05156-2226 | |
| (802) 886-4567 | |
| (802) 886-4520 |
| Full Name | Abigail Bargiel Burns |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 390 River St, Springfield, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932422235 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 026-0042083 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Abigail Bargiel Burns, RN 390 River St, Springfield, VT 05156-2226 Ph: (802) 886-4567 | Abigail Bargiel Burns, RN 390 River St, Springfield, VT 05156-2226 Ph: (802) 886-4567 |
News Archive
President Barack Obama and GOP congressional leaders signal what they're looking for in a budget deal to avert the looming "fiscal cliff," offering their respective takes on tax increases, spending cuts and changes to entitlement programs.
A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.
MDLiveCare, an on-demand telehealth company, announced today at the Health2.0 conference in San Francisco a partnership with Google Health.
Researchers at the University of Maryland at College Park have discovered that Normal Human Bronchial Epithelial (NHBE) cells cultured in medium with elevated zinc level, at the high end of plasma zinc attainable by oral supplementation, demonstrated inhibition of cell growth, up-regulation of growth arrest and DNA damage-induced gene (Gadd45) mRNA and protein expression, and blockage of G2/M cell cycle progression.
Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD).
› Verified 8 days ago
Maureen Shattuck, RN,CDE Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 100 River St, Springfield, VT 05156 Phone: 802-886-8988 Fax: 802-886-8909 | |
Rebecca L. Brown, BSN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 390 River Street, Springfield, VT 05156 Phone: 802-886-4500 Fax: 802-886-4560 | |
Sue T Euphrat, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 10 Lincoln St, Springfield, VT 05156 Phone: 802-886-4500 Fax: 802-886-4520 | |
Sylvia Ann Flint, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 390 River Street, Health Care And Rehabilitation Services Of Se Vt Inc, Springfield, VT 05156 Phone: 802-886-4567 Fax: 802-886-4520 | |
Jill A. King, BA RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 10 Lincoln Street, Springfield, VT 05156 Phone: 802-885-7280 Fax: 802-885-2683 | |
Claire M Lewis, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 390 River Street, Springfield, VT 05156 Phone: 802-886-4500 Fax: 802-886-4560 | |
Michael M O'sullivan, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 10 Lincoln St, Springfield, VT 05156 Phone: 802-885-7280 Fax: 802-885-2593 |